Business Context and Reporting Period
Company: Artelo Biosciences, Inc. (Nasdaq: ARTL)
Filing Type: Form 8-K (Current Report)
Date of Report: July 18, 2025
Event: Entry into a Material Definitive Agreement (At-The-Market Offering Program)
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or margin data. The report focuses exclusively on a new capital raising mechanism.
- Offering Size: Up to $6,500,000 in aggregate common stock.
- Commission Rate: 2.0% of the gross sales price per share.
- Sales Agent: R.F. Lafferty & Co., Inc.
Material Changes
The Company entered into a Sales Agreement on July 18, 2025, establishing an "at-the-market" (ATM) equity program. This allows the Company to sell shares from time to time through the sales agent on The Nasdaq Capital Market or other existing trading markets. This action utilizes a previously effective Form S-3 registration statement filed on July 14, 2023, which registered $75,000,000 of common stock.
Guidance, Outlook, and Risks
Management Commentary: The Company retains the right to instruct the Manager not to sell shares if sales cannot be effected at or above a designated price. The Company may also suspend the offering at any time.
Termination Provisions: The agreement terminates upon the sale of all shares subject to the agreement or upon five (5) days' prior notice by either party.
Risks and Contingencies: The filing explicitly states that the Sales Agreement is not intended as a document for investors to obtain factual information about the Company's current state of affairs. Investors are directed to other SEC filings for such information. The offering is subject to applicable limits when using Form S-3.
Investor Verification Checklist
- Verify the current cash position and burn rate in the most recent 10-Q or 10-K to assess the necessity of this capital raise.
- Review the prospectus supplement filed on July 18, 2025, for specific terms regarding price floors or suspension triggers.
- Monitor future 8-K filings for actual sales volumes and proceeds generated under this ATM program.
- Check the dilution impact of selling up to $6.5 million of shares based on the current market price.